celgosivir has been researched along with zalcitabine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bowlin, TL; Kang, MS; Liu, PS; Sunkara, PS; Taylor, DL; Tyms, AS | 1 |
| Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS | 1 |
3 other study(ies) available for celgosivir and zalcitabine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
6-0-butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIVs.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Cell Line; Cell Line, Transformed; Dose-Response Relationship, Drug; Gene Products, env; Glucosamine; Glycoside Hydrolase Inhibitors; HIV Envelope Protein gp120; HIV Envelope Protein gp160; HIV-1; Humans; Indolizines; Mice; Moloney murine leukemia virus; Protein Precursors; Viral Plaque Assay; Zalcitabine | 1991 |
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Topics: Antiviral Agents; Cells, Cultured; Cytotoxicity Tests, Immunologic; Didanosine; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Humans; Indolizines; Isoquinolines; Leukocytes, Mononuclear; Molecular Structure; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Uracil; Zalcitabine; Zidovudine | 1995 |